Literature DB >> 30005031

Early Phacoemulsification After Acute Angle Closure in Patients With Coexisting Cataract.

Hellen C S Römkens1, Henny J M Beckers1, Jan S A G Schouten2, Rudy M M A Nuijts1, Tos T J M Berendschot1, Christophe M Breusegem1, Carroll A B Webers1.   

Abstract

PURPOSE: The purpose of this study is to evaluate the effect of early phacoemulsification on the management of acute angle closure glaucoma in patients with coexisting cataract after initial treatment with medical therapy and laser peripheral iridotomy. PATIENTS AND METHODS: This study involved a retrospective analysis of patients presenting to the Maastricht University Medical Center+ with acute angle closure and coexisting cataract between 2005 and 2015. Patients were included after initial treatment with a standard protocol comprising topical and systemic medical therapy and laser peripheral iridotomy. Patients underwent small-incision phacoemulsification with intraocular lens implantation into the capsular bag by experienced surgeons within 3 months of the acute angle closure episode. The effect on intraocular pressure, number of glaucoma medications, visual acuity, and complications was assessed.
RESULTS: A total 35 patients were included in the study (mean age, 71±10 y; 20% male; mean refractive error, +1.6±1.8 diopters). The mean duration between acute angle closure episode and phacoemulsification was 37±22 days. There were no complications. Intraocular pressure decreased in all patients from 17.0±8.2 mm Hg to 13.2±3.9 mm Hg after 3 months (P=0.008), whereas the mean number of glaucoma medications decreased from 2.9±1.1 to 0.7±0.9 (P<0.001), with 56% of patients discontinuing all medications. Visual acuity improved from 0.9±0.9 logMAR to 0.2±0.3 logMAR (P<0.001).
CONCLUSIONS: Early phacoemulsification with intraocular lens implantation results in a reduced intraocular pressure and number of glaucoma medications after an acute angle closure glaucoma crisis in patients with coexisting cataract. Although surgery may be challenging, the results are promising, with significant improvement in visual acuity in most patients.

Entities:  

Mesh:

Year:  2018        PMID: 30005031     DOI: 10.1097/IJG.0000000000000998

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

1.  Clinical outcome of phacoemulsification combined with intraocular lens implantation for primary angle closure/glaucoma (PAC/PACG) with cataract.

Authors:  Yuan He; Ruixue Zhang; Chuntao Zhang; Jun Jia; Huifeng Liu; Beilei He; Zhuoya Quan; Jian Zhang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Trends in the characteristics of acute primary angle closure in Korea over the past 10-years.

Authors:  Jun Young Ha; Mi Sun Sung; Hwan Heo; Sang Woo Park
Journal:  PLoS One       Date:  2019-10-09       Impact factor: 3.240

3.  Early versus Delayed Phacoemulsification and Intraocular Lens Implantation for Acute Primary Angle-Closure.

Authors:  Yun-Hsuan Lin; Cheng-Hsiu Wu; Shih-Ming Huang; Chen Hsieh; Henry Shen-Lih Chen; Wan-Chen Ku; Ming-Hui Sun; Wei-Wen Su
Journal:  J Ophthalmol       Date:  2020-03-24       Impact factor: 1.909

4.  Anterior Segment Optic Coherence Tomography Changes Before and After Phacoemulsification in Primary Open-Angle Glaucoma.

Authors:  Sibel Zirtiloglu; Ozen Ayranci Osmanbasoglu; Tulay Alpar Akcetin; Yeliz Acar; Mustafa Suat Alikma; Erkan Unsal; Kadir Eltutar
Journal:  Beyoglu Eye J       Date:  2019-08-09

5.  Anterior segment pars plana vitrectomy combined with posterior capsulorhexis, phacoemulsification and trabeculectomy in treatment of medically uncontrolled acute primary angle-closure glaucoma: A retrospective study.

Authors:  Jie Qu; Zhen Tian; Xin Li; Yong Zhang
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

6.  Time trends and heterogeneity in the disease burden of glaucoma, 1990-2017: a global analysis.

Authors:  Yichi Zhang; Guangming Jin; Min Fan; Yifan Lin; Xin Wen; Zijing Li; Peng Zeng; Danying Zheng; Yuqing Lan
Journal:  J Glob Health       Date:  2019-12       Impact factor: 4.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.